nejm semaglutide heart failure Updates in Medicine | 🩺 Oral Cuts CV Risk in High-Risk T2DM – SOUL Trial (NEJM, Mar 2025) 🔗 Original article link in bio 📌 Key Highlights: 🔹 Read the full results of

We deprescribe really slowly so they have confidence theyre not going to gain back what theyve lost, she says

I pay close attention to how they approach raw material sourcing, how their formulation team evaluates ingredient compatibility, and how they manage quality control throughout production

Efficacy and Side Effects : Huberman expresses excitement about the efficacy of GLP-1 agonists, acknowledging they promote fat loss but also lead to muscle loss, a concern for individuals who prioritize maintaining muscle mass

(The brand-name GLP-1s arent available as generics because the patents havent expiredNovo Nordisk has its US patent on semaglutide until 2032, and Eli Lilly on tirzepatide, until 2036.) But to be clear, compounders do still operate within a regulatory framework, albeit a less stringent one

Yes, but stopping after one month may lead to regained appetite and slowed progress